Summary & Overview
HCPCS S0157: Becaplermin Gel 0.01%, 0.5 gm
HCPCS Level II code S0157 identifies a 0.5 gram unit of becaplermin gel 0.01%, a topical recombinant platelet-derived growth factor used in wound care. Nationally, this code matters because it standardizes billing for an advanced biologic therapy indicated for certain chronic diabetic lower-extremity ulcers, influencing coverage decisions, utilization monitoring, and cost management for outpatient wound care services. Key national payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn what the code represents clinically, where the product is typically administered, and which major payers are relevant for coverage considerations. The publication summarizes benchmarks and billing practice observations, highlights common payer considerations for coverage and documentation, and provides clinical context for appropriate use of the product. Data not available in the input is noted where applicable for payer-specific rates, claim volume, and detailed policy language. The content is intended to inform billing, revenue cycle, and clinical staff about the code’s purpose, typical sites of service, and the payer landscape at a national level.
Billing Code Overview
HCPCS Level II code S0157 represents Becaplermin gel 0.01%, 0.5 gm. This item is a topical growth factor formulation used for wound care, specifically for promoting healing in chronic lower extremity diabetic ulcers that extend into the subcutaneous tissue or beyond and have adequate blood supply.
-
Service type: Topical biologic wound care product
-
Typical site of service: Outpatient wound care clinics, specialty wound centers, physician offices, and home health settings where topical wound treatments are applied by clinicians or caregivers.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic, non-healing diabetic foot ulcer being treated in an outpatient wound care clinic. The patient has a history of type 2 diabetes mellitus with peripheral neuropathy and poor glycemic control, and has had the ulcer present for several weeks despite standard wound care (debridement, offloading, moist wound therapy). The clinician applies S0157 (becaplermin gel 0.01%, 0.5 gm) topically to the wound following sharp or mechanical debridement, documents wound size, depth, and signs of infection, and provides instructions for dressing changes and offloading. The product is typically supplied and applied in clinic by a licensed clinician (podiatrist, wound care nurse, or physician) or dispensed to the patient with documented instructions for home application when clinically appropriate. Follow-up visits occur weekly to monitor healing, assess for adverse reactions, and determine duration of use up to the recommended treatment course.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no special modifier applies. |
22 | Increased procedural services |